Sesen Bio, Inc. Securities Class Litigation

Introduction

Securities class action litigation has been filed on behalf of investors in the securities of Sesen Bio, Inc. (“Sesen Bio”) (NASDAQ: SESN). If you purchased or otherwise acquired Sesen Bio securities between December 21, 2020 and August 17, 2021, inclusive (the “Class Period”), you may move the court for appointment as lead plaintiff by no later than October 18, 2021.

You may retain Lieff Cabraser Heimann & Bernstein, LLP, or other attorneys, as your counsel in the action. Recognized by the National Law Journal as one of the nation’s top plaintiffs’ law firms, Lieff Cabraser is committed to safeguarding the rights of investors and upholding the integrity of the market. We have significant experience and a successful track record of representing institutional and individual investors in securities and financial fraud litigation.

Sesen Bio investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should use the form below, or email investorinfo@lchb.com, or call Lieff Cabraser partner Sharon M. Lee toll-free at 1-800-541-7358.

Background on the Sesen Bio Securities Class Litigation

Sesen Bio, headquartered in Cambridge, Massachusetts, is a late-stage clinical company that purports to develop targeted fusion protein therapeutics for cancer treatments. The Company’s lead product is the drug Vicineum, a treatment for bacillus Calmette-Gurin (“BCG”)-unresponsive non-muscle invasive bladder cancer (“NMIBC”). In August 2019, Sesen Bio reported preliminary efficacy data from its ongoing Phase 3 clinical trial for Vicineum. In December 2020, the Company submitted its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for Vicineum.

The actions allege that throughout the Class Period, defendants failed to disclose to investors: (1) more than 2,000 violations of trial protocol in Sesen Bio’s clinical trial for Vicineum, 215 of which were classified as “major”; (2) three clinical investigators were found guilty of “serious noncompliance,” including “back-dating data”; (3) Sesen Bio’s submission of tainted data related to the BLA for Vicineum; and (4) incidents of Vicineum leaking into patients’ bodies in the Company’s clinical trials, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury. Furthermore, defendants failed to reveal that, as a result of the foregoing, the Company’s BLA for Vicineum was not likely to be approved and that there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to show the efficacy and safety of Vicineum.

On August 13, 2021, Sesen Bio revealed that the FDA declined to approve its BLA for Vicineum. In its complete response letter (“CRL”), the FDA outlined “recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls (CMC) issues pertaining to a recent pre-approval inspection and product quality.” On this news, the Company’s stock price fell $2.80 per share, or 57%, from its closing price of $4.91 on August 12, 2021, to close at $2.11 per share on August 13, 2021, on unusually heavy trading volume.

Then, on August 16, 2021, Sesen Bio announced it needed “to do a clinical trial to provide the additional efficacy and safety data necessary for the FDA to assess the benefit-risk profile, which is the basis for approval.”  As a result, the Company expected that it could not resubmit its BLA until 2023.  On this news, the Company’s stock price fell $0.89 per share, or 42%, from its closing price of $2.11 on August 13, 2021, to close at $1.22 per share on August 16, 2021, on unusually heavy trading volume.

Finally, on August 18, 2021, before the market opened, the health and medicine news site STAT published an article revealing “thousands of violations of study rules, damning investigator conduct, and worrying signs of toxicity the company [Sesen] did not publicly disclose” regarding its clinical trial for Vicineum.  The STAT article was reportedly based on “hundreds of pages of internal documents” and cited “three people familiar with the matter.”  On this news, the Company’s stock price fell $0.20 per share, or 13%, from its closing price of $1.51 on August 17, 2021, to close at $1.31 per share on August 18, 2021, on unusually heavy trading volume.

Contact us

    First Name (required)

    Last Name (required)

    Email address (required)

    Street Address

    City

    State

    Zip

    Telephone

    How did you find our site?

    Are you currently represented by an attorney?

    II.TRANSACTIONS IN SESEN BIO SECURITIES

    From December 21, 2020 through August 17, 2021, inclusive, I made the following transactions in Sesen Bio securities:

    PURCHASES

    Date
    No. of Shares
    Price

    show more rows

    SALES

    Date
    No. of Shares
    Price

    show more rows

    During the 90 days after August 17, 2021, I made the following transactions in Sesen Bio securities:

    PURCHASES

    Date
    No. of Shares
    Price

    show more rows

    SALES

    Date
    No. of Shares
    Price

    show more rows

    Comments & questions:


    About Lieff Cabraser

    Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, Nashville, and Munich, is an internationally-recognized law firm committed to advancing the rights of investors and promoting corporate responsibility. Recognized as a “Plaintiffs’ Powerhouse” by Law360, Lieff Cabraser has litigated some of the most important civil cases in the United States and has assisted clients in recovering over $124 billion in verdicts and settlements. Benchmark Litigation named Lieff Cabraser its “2020 California Plaintiff Firm of the Year,” and in early 2021, The American Lawyer named our firm its “Boutique Litigation Firm of the Year.” Lieff Cabraser is committed to access to justice for all.

    PRACTICE GROUP BROCHURE